Aethlon Medical, Inc. announced in October 2024 that its board of directors appointed James Frakes as the company's permanent Chief Executive Officer. Mr. Frakes had previously served as Interim Chief Executive Officer since November 2023.
This appointment provides stable leadership as Aethlon Medical continues to advance its Hemopurifier clinical development programs. The company is focused on its oncology trial efforts in Australia and implementing cost-cutting measures to streamline operations.
Mr. Frakes also holds the position of Chief Financial Officer, indicating a consolidated leadership role in guiding the company's financial and strategic direction.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.